Literature DB >> 28918323

Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.

Jee Sun Min1, Jiseon Kim1, Jung Ho Kim1, Doyun Kim1, Yu Fen Zheng1, Ji Eun Park2, Wooin Lee2, Soo Kyung Bae3.   

Abstract

A highly sensitive and rapid LC-MS/MS method was developed and validated to determine the levels of carfilzomib in mice plasma by using chlorpropamide as an internal standard. Carfilzomib and chlorpropamide were extracted from 5 μL of plasma after protein precipitation with acetonitrile. Chromatographic separation was performed on Phenomenex Luna C18 column (50×2.0mm id, 3μm). The mobile phase consisted of 0.1% formic acid in acetonitrile -0.1% formic acid in water (1:1v/v) and the flow rate was 0.3mL/min. The total chromatographic run time was 2.5min. Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard). The lower limit of quantification was 0.075ng/mL and the linear range was 0.075-1250ng/mL (r≥0.9974). All validation data, including selectivity, precision, accuracy, matrix effect, recovery, dilution integrity, stability, and incurred sample reanalysis, were well within acceptance limits. This newly developed bioanalytical method was simple, highly sensitive, required only a small volume of plasma, and was suitable for application in pharmacokinetic studies in mice that used serial blood sampling.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carfilzomib; LC–MS/MS; Mouse plasma; Pharmacokinetics; Small volume

Mesh:

Substances:

Year:  2017        PMID: 28918323     DOI: 10.1016/j.jpba.2017.08.048

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.

Authors:  Ji Eun Park; Joonyoung Park; Yearin Jun; Yunseok Oh; Gongmi Ryoo; Yoo-Seong Jeong; Hytham H Gadalla; Jee Sun Min; Jung Hwan Jo; Myung Geun Song; Keon Wook Kang; Soo Kyung Bae; Yoon Yeo; Wooin Lee
Journal:  J Control Release       Date:  2019-04-04       Impact factor: 9.776

2.  Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas.

Authors:  Wen-Ting Cheng; Hsiu-O Ho; Shyr-Yi Lin; Der-Zen Liu; Ling-Chun Chen; Ming-Thau Sheu
Journal:  Int J Nanomedicine       Date:  2021-10-05

3.  Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model.

Authors:  Yearin Jun; Jun Xu; Hyungjun Kim; Ji Eun Park; Yoo-Seong Jeong; Jee Sun Min; Naeun Yoon; Ji Yoon Choi; Jisu Yoo; Soo Kyung Bae; Suk-Jae Chung; Yoon Yeo; Wooin Lee
Journal:  J Pharm Sci       Date:  2020-01-13       Impact factor: 3.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.